Here are four stocks with good technical strength pointing to higher prices.

1. Aratana Therapeutics  (PETX) has been rallying for four months after dropping from more than $20 in September to near $2.50 in February. Shares of the company, which makes biopharmaceutical products for pets, has been climbing along the bottom of their channel after pulling back in late April and early May. There's a double-top at around $7.80. If the stock breaches that level, it could rise to $9 and then $11.50.

2. Cynosure (CYNO) , which broke out in late April and pulled back for much of May, broke out of the short-term declining channel a week ago on FDA approval for marketing its new laser tattoo-removal system. It pulled back for several sessions but then popped on Wednesday on no news, gaining $2.72, or 5.6%, to $50.49 on 777,236 shares traded, the third biggest daily volume of the year. It closed right at lateral resistance, and could get a run here. The targets are $55 and then the channel top near $59.

3. Five9 (FIVN - Get Report) popped another 73 cents, or 7%, to $10.92 on Wednesday on no news. Volume of 855,000 shares was the second largest volume this year for this application software company. The stock closed above its May 11 intraday high of $10.90, and this could lead to the next target of $12 and eventually the mid-teens.

4. Infoblox (BLOX) built a nice base this year after a steep decline in the second half of 2015. The stock popped out of the base with a big gap higher on May 12 on reports of an offer to take the communications-equipment company private. After flagging for three weeks, the stock rallied on Wednesday, gaining 73 cents, or 3.8%, to $19.54 on 2.7 million shares on news it hired Morgan Stanley for activist defense. It was a big reversal off an intraday low of $18.20. In after-hours trading, the stock had a bit of a scare, but came back well. If it can get through the May 26 intraday high of $20.05, it should make it up to $22 and then $24.

See Harry's video chart analysis on these stocks.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage. At the time of publication, the author held no shares of stocks mentioned.